← Back to KLRA

Kailera Therapeutics, Inc. - Common stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 12/08/2026Mar 2026Filed 12/08/2026Jun 2025Filed 12/08/2026Mar 2025Filed 12/08/2026
−$111−$79−$29−$18
−$1.09−$3650.00−$28947.00−$17983.00
102—00

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.